Disease Diagnosis TRIZ Cases

Proteomic analysis detects PIGR and APOA biomarkers in plasma, enabling early identification of subclinical atherosclerosis without complex imaging procedures.

Measuring PSA with beta-N-acetylgalactosamine residues replaces invasive biopsies, enabling accurate cancer staging through non-invasive blood tests.

A method tracks cancer stem cell populations using flow cytometry and in vivo imaging to assess therapeutic response.

A urine analysis method uses albumin-sensitive reagents to detect proteins and calculate diagnostic indicators.

Salivary biomarkers replace invasive tissue biopsies with non-invasive protein analysis to detect occult disease and improve diagnostic accuracy.

A diagnostic method determines procalcitonin levels in bodily fluids to identify patients at risk of adverse outcomes from unnecessary antibiotic administration.

CRMP2 and synaptotagmin biomarkers detect neural injury via calpain cleavage, replacing costly imaging to resolve diagnostic time and expense trade-offs.

TM9SF4-positive extracellular vesicles isolate tumor biomarkers through antibody binding, resolving invasive tissue sampling constraints.

A dual antibody composition isolates circulating tumor cells from peripheral blood mononuclear cells using magnetic bead enrichment.

Detect polyomavirus agnoprotein in body fluids to monitor active reactivation, avoiding invasive brain biopsies and improving diagnostic reliability.

Human monocytic cell lines detect glatiramer acetate potency via sIL-1Ra expression levels measured after interferon gamma stimulation.

Detecting amino acid adducts in plasma and urine samples enables objective ASD diagnosis.

Parallel proANP and BNP detection improves diagnostic precision for NYHA I patients, enabling accurate risk stratification.

Early biomarker assays detect UCH-L1 and GFAP levels to guide clinical imaging decisions.

Withaferin A derived fluorophore probes label type III intermediate filament proteins and mitochondrial structures via fluorescence.

Extracting diagnostic data from stool samples resolves the trade-off between invasive colonoscopy risks and accurate inflammatory bowel disease monitoring.

Combining fibrin monomer determination with activated partial thromboplastin time improves diagnostic sensitivity for preoperative screening.

A saliva biomarker index quantifies fatigue levels through specific peptide detection.

Detecting specific blood proteins predicts cerebral edema risk in stroke patients.

A multi-biomarker detection method predicts bladder cancer recurrence risk using antibody microarrays and statistical analysis of patient tissue samples.

Integrating inflammation and lipid markers into a composite risk score overcomes limited predictive power of traditional clinical factors.

Proximity ligation assay detects estrogen receptor family members within transcription factor complexes to determine pathway activation status.

Modulating renal epithelial cell cycle phases with specific compounds protects against acute kidney injury by inducing G0/G1 arrest or promoting recovery.

In silico screening identifies and excludes neo-epitopes engaging regulatory T cells, preventing immune suppression in personalized neoplasia vaccines.

Combining cardiac Troponin and natriuretic peptide measurements enables precise differential diagnosis of acute cardiovascular events.

Detecting anti-HE4 antibodies with specific polypeptides resolves low CA125 specificity, improving early ovarian cancer diagnosis reliability.

Heart fatty acid binding protein measurement alongside electrocardiogram and troponin tests identifies cardiovascular conditions in chest pain patients.

Correlating gender, age, and biomarkers like natriuretic peptides improves mortality prediction accuracy beyond traditional cardiovascular risk factors.

Streptavidin-HRP complexes amplify signals from biotinylated antibodies to resolve accuracy and reproducibility contradictions in ANGPTL8 quantification.

A biomarker panel differentiates acute exacerbation of COPD from stable states using targeted mass spectrometry.

Calculating a disease-state index from fecal D-form and L-form amino acids detects kidney failure earlier than serum creatinine markers.

Segmenting cytokine signaling via multi-parameter profiling resolves prediction accuracy issues in colon cancer treatment.

Analyzing pre-parturition blood concentrations of 25 amino acids and 13 chemistry parameters to identify ketosis risk before clinical symptoms appear.

Detecting anti-SH3BP5 antibodies resolves the contradiction between indirect risk factor measurement and accurate disease progression assessment.

Targeted monoclonal antibodies inhibit neutrophil activation and endothelial lesions in granulomatosis with polyangiitis.

Sodium polyoxyethylene lauryl sulfate stabilizes troponin proteins at room temperature, eliminating freezing requirements and thawing delays.

Platelet function assays using CRP-XL and convulxin agonists detect sepsis severity through receptor activation.

Measuring immune biomarkers in blood samples replaces complex imaging to enable early detection of neurodegenerative diseases.

A capillary flow cell analyzer uses fluorescent moieties to detect biological markers at femtomolar concentrations.

Extracting specific proteins via disposable immunoassays reduces diagnostic time and cost while maintaining accuracy.

DNA aptamer platform detects angiopoietin-2 and thrombospondin-2 in plasma samples.

A serological marker panel calculates risk scores from pre-operative samples to identify patients at risk of post-operative recurrence.

Segmenting Glycoprotein 2 into distinct isoforms enables accurate differentiation of autoimmune diseases like Crohn's and Celiac disease.

Purified in vitro carbamylated alpha-1-antitrypsin polypeptides form complexes with anti-CarP antibodies to enable precise detection.

PKA pathway activation triggers mesenchymal to epithelial transition, sensitizing resistant cancer stem cells to conventional chemotherapy.